Japan Platelet Rich Plasma (prp) Market Size & Outlook
Japan platelet rich plasma (prp) market, 2018-2030 (US$M)
Related Markets
Japan platelet rich plasma (prp) market highlights
- The Japan platelet rich plasma (prp) market generated a revenue of USD 28.4 million in 2023 and is expected to reach USD 90.7 million by 2030.
- The Japan market is expected to grow at a CAGR of 18.1% from 2024 to 2030.
- In terms of segment, pure prp was the largest revenue generating type in 2023.
- Leukocyte Rich PRP is the most lucrative type segment registering the fastest growth during the forecast period.
Platelet rich plasma (prp) market data book summary
| Market revenue in 2023 | USD 28.4 million |
| Market revenue in 2030 | USD 90.7 million |
| Growth rate | 18.1% (CAGR from 2023 to 2030) |
| Largest segment | Pure prp |
| Fastest growing segment | Leukocyte Rich PRP |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Pure PRP, Leukocyte Rich PRP |
| Key market players worldwide | Johnson & Johnson, Arthrex, Terumo Corp, Zimmer Biomet Holdings Inc, Stryker Corp, EmCyte Corporation, Dr. PRP USA, Juventix Regenerative Medical, APEX Biologix, Celling Biosciences |
Other key industry trends
- In terms of revenue, Japan accounted for 4.4% of the global platelet rich plasma (prp) market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, India platelet rich plasma (prp) market is projected to lead the regional market in terms of revenue in 2030.
- Japan is the fastest growing regional market in Asia Pacific and is projected to reach USD 90.7 million by 2030.
Pure prp was the largest segment with a revenue share of 51.76% in 2023. Horizon Databook has segmented the Japan platelet rich plasma (prp) market based on pure prp, leukocyte rich prp covering the revenue growth of each sub-segment from 2018 to 2030.
In 2014, the "Act on the Safety of Platelet-rich Plasma (PRP)" and the "Pharmaceuticals, Medical Devices, and Other Therapeutic Products Act” were established by Japan for the regulation of platelet concentration therapies owing to their increasing popularity. Stringent regulations have been imposed for the correct use of PRP in terms of efficacy & specificity toward certain applications and dosage.
Furthermore, Japanese researchers have proposed point-of-care testing of PRP quality in research published in April 2019. In this study, researchers have emphasized the need for point-of-care quality testing to obtain supportive evidence for platelet-rich plasma therapy.
The point-of-care testing of platelet-rich plasma is an inexpensive and useful method for determining platelet count. This method can determine platelet count in PRP preparations, further supporting the therapy. Such recommendations are expected to positively impact the adoption of PRP therapies in the country, leading to significant market growth.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Platelet Rich Plasma (PRP) Market Scope
Platelet Rich Plasma (PRP) Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Japan platelet rich plasma (prp) market size, by type, 2018-2030 (US$M)
Japan Platelet Rich Plasma (PRP) Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
